Erich Tauber is co-founder and has been CEO of Themis since its inception in 2009.
He has been working in the pharmaceutical and biotechnology industry since 2000 and has served in various roles with increasing responsibilities at AstraZeneca, Baxter, Intercell and Nycomed. In particular, he was responsible for the development and commercialization of Ixario, the first Japanese Encephalitis vaccine. He is a renowned expert in the field of vaccine and product development and a frequent author of scientific publications and speaker at corporate conventions.
He received his medical training at the University of Vienna and holds a medical Doctorate from the Medical University in Vienna. Before joining the industry, he was a pediatric research fellow at the Vienna University Children’s Hospital and the Southampton Children’s Hospital, UK.
In the last 20 years Philippe Dro initiated and executed several strategic transactions. Prior to its acquisition by GSK, he served at the vaccine developer GlycoVaxyn AG as CEO and member of the Supervisory Board. Before that, he led EndoArt S.A., a medtech company, in the position of CEO and Chairman of the Board through a successful sale process of the company to Allergan. When Actelion acquired Axovan AG, he was acting CFO and Head of Business Development. Prior to that, he served at Novartis, Skyepharma and Antares Pharma in a number of responsible functions.
Dr. Smith is a biopharmaceutical CMC and process development expert who, over the course of his career, advised a broad range of small to large biotech and pharmaceutical companies globally. He specializes in the CMC aspects of medical product development covering vaccines, therapeutics and diagnostics working with researchers and product developers through to manufacturing. Prior to joining Themis as CTO, he founded GreyRigge Associates in 2010, a consulting firm focused on providing both technical and commercial expertise for the biopharmaceutical development process to his clients. Dr. Smith held a number of senior roles internationally in companies including SingVax, Davos Life Science, Emergent Biosolutions and GlaxoSmithKline. He holds Doctorate and Bachelor degrees in biochemistry from the University of Bath and University of West England, Bristol, respectively.
Alexander Kort is SVP Corporate Development at Themis Bioscience GmbH in Vienna, Austria. His responsibilities include all business development and licensing activities of Themis and oversight of all internal corporate development activities. Alexander has more than 10 years’ experience in the vaccine industry from vaccine development to vaccine manufacturing.
Prior to Themis Alexander held various positions with increasing responsibility in project management, process development and manufacturing and strategic operations at IDT Biologika GmbH, a global vaccines and biologics CDMO. Alexander graduated in Biosystems Engineering and holds an IPMA certificate for Project Management.
David A. Maier joined Themis in 2015 to direct all financial matters for the company. Mr. Maier started his career at a Big 4 audit firm and thereafter managed a local private equity fund in Austria and held several positions on the supervisory board level at portfolio companies. Beside his finance position at Themis, he is specialized in company valuation and acts as an expert witness in this field.
Additionally, he is a lecturer at the University of Applied Science (FH Wien) and publishes specialist articles concerning valuation and finance. He attended a chemical technical college and studied business administration at WU Wien with focus on finance and controlling.
Dr. Mandl is an internationally renowned expert on arboviruses with over 25 years of experience in vaccine development. He previously served as Global Head of Research, Early and Exploratory Clinical Development at Novartis Vaccines where he directed a team of over 300 employees working on more than 15 viral and bacterial vaccine pipeline projects and platform technologies.
Prior to Novartis, he acted as Professor and Deputy Head of the Department of Virology at the Medical University of Vienna. Dr. Mandl received his M.D. and Ph.D. from the University of Vienna and his M.S. in biochemistry from Pennsylvania State University.
Matthias Müllner has been leading Themis CMC efforts since 2013, developing a scalable and robust manufacturing process. He joined Themis in 2011 as Senior Scientist Vaccine development from the Children’s Cancer Research Institute (CCRI), Vienna. In his postdoctoral scientist position he developed treatments against adenoviral infections of immunocompromised patients.
He is a lecturer at the university of applied science (FH Wien) and holds a PhD and a Master in molecular biology from the University of Vienna.
Katrin Ramsauer joined Themis in 2010 as Senior Scientist Vaccine Development. Since 2013 she heads Themis preclinical and clinical development advancing the companies lead program in Chikungunya through a successful Phase 1 study. Prior to Themis she was a postdoctoral scientist at Novartis Vaccine and Diagnostics Inc. in Cambridge, MA where she investigated the mechanisms of action of vaccine candidates and small molecule compounds.
Dr. Ramsauer also held postdoctoral fellowship positions at the Clinical Institute of Virology, Medical University of Vienna and Max F. Perutz Laboratories, University of Vienna. She holds a PhD in molecular biology and immunology and a Master in microbiology from the University of Vienna.